Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Head & Neck 2Dermatologic 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Hematologic Neoplasms 1

Interventions

Cyclophosphamide 122Cytarabine 112fludarabine 91fludarabine phosphate 80Rituximab 75Azacitidine 75venetoclax 55Methotrexate 52Filgrastim 48Whole-Body Irradiation 45Busulfan 45Tacrolimus 35Etoposide 35Mycophenolic Acid 34Lenalidomide 32Imatinib Mesylate 32Antilymphocyte Serum 32Granulocyte Colony-Stimulating Factor 31Decitabine 31Peripheral Blood Stem Cell Transplantation 29Dexamethasone 29Cyclosporine 29Vincristine 26Melphalan 26Clofarabine 25Alemtuzumab 25Mitoxantrone 24Stem Cell Transplantation 22Radiotherapy 22Dasatinib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × alovudine × Other hematologic neoplasm × Clear all
NCT00070239 2013-12-16

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

National Cancer Institute (NCI)

Phase 1 Terminated
100 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡